Results 111 to 120 of about 1,273,827 (295)

Pharmacological affinity fingerprints derived from bioactivity data for the identification of designer drugs. [PDF]

J Cheminform, 2022
He K.
europepmc   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Designer drugs : analytical and biological aspects [PDF]

, 2012
In the recent years, analytical toxicologists have been facing difficulties in detecting designer drugs due to the chemical modifications on the existing structures and the speed in which they are released into the market, requiring the development and ...
Bulcão, Rachel Picada, Garcia, Solange Cristina, Chasin, Alice A. da Matta, Limberger, Renata Pereira, Baierle, Marília, Arbo, Marcelo Dutra, Thiesen, Flávia Valladão, Tavares, Rejane Giacomelli   +7 more
core   +1 more source

Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs. [PDF]

J Clin Med, 2022
Welz A, Koba M, Kośliński P, Siódmiak J.   +3 more
europepmc   +1 more source

Autophagy and mitophagy in pancreatic β‐cell homeostasis and their involvement in diabetes pathophysiology

FEBS Letters, EarlyView.
This review focuses on the role of autophagy and mitophagy in maintaining pancreatic β‐cell function and homeostasis. We discuss how genetic defects affecting these pathways contribute to the development of type 1, type 2, monogenic, and gestational diabetes. We further explore their potential as therapeutic targets. Created in BioRender.
Yunkyeong Lee, Mingming Tong, Anna L. Gloyn   +2 more
wiley   +1 more source

Designer drugs pose a severe public danger after hospitalisation of six.

, 2016
The hospitalisation of six people after allegedly taking 2C-B is a prime example of the potential dangers of consuming a so-called designer drug....
Keating, Dr U
core  

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

Knowledge, attitudes, and practices of Chinese college students towards novel psychoactive substances

BMC Public Health
Background This study aimed to investigate the knowledge, attitudes, and practices (KAP) among Chinese college students regarding novel psychoactive substances (NPS), where practices specifically refer to behaviors related to NPS access and usage ...
Liqin Lu, Xinhao Zhou, Jue Deng, Binling Zhu, Liang Meng, Xianghui Lai, Xiaoli Zhu   +6 more
doaj   +1 more source

Designer Receptors Exclusively Activated by Designer Drugs Approach to Treatment of Sleep-disordered Breathing. [PDF]

Am J Respir Crit Care Med, 2021
Fleury Curado T, Pho H, Freire C, Amorim MR, Bonaventura J, Kim LJ, Lee R, Cabassa ME, Streeter SR, Branco LG, Sennes LU, Fishbein K, Spencer RG, Schwartz AR, Brennick MJ, Michaelides M, Fuller DD, Polotsky VY.   +17 more
europepmc   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

FEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri, Ayaka Nagasato‐Ichikawa, Keita Iida, Shuhei Kimura, Akira Imamoto, Mariko Okada   +5 more
wiley   +1 more source